StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
KAPABullishCorporate Developmentsnews
High materiality7/10

Kairos and Bayer to evaluate ENV-105 with XOFIGO in bone mCRPC

Jul 22, 2026, 8:37 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

A high-profile collaboration with Bayer plus positive Phase 2 signals can re-rate Kairos on clinical validation and potential future milestones; real upside hinges on readouts and regulatory progress.

AI summary

What happened, with direct paths to the underlying reporting

Kairos Pharma and Bayer will evaluate ENV-105 with XOFIGO for bone-dominant metastatic castration-resistant prostate cancer. Phase 2 data show median progression-free survival exceeding 13 months, and XOFIGO's ongoing momentum adds optionality. The collaboration targets a $570M–$1.3B addressable market that could drive valuation uplift if data stay compelling.

  • Kairos and Bayer to evaluate ENV-105 with XOFIGO for bone metastatic mCRPC.
  • ENV-105 targets CD105/BMP signaling to re-sensitize resistant tumors.
  • Addressable market cited at $570M–$1.3B globally.
  • Phase 2 data: median PFS >13 months; data presented at 2025 ESMO.
  • PEACE-3 data show 24% mortality risk reduction with enzalutamide.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event